KR102244216B1 - 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도 - Google Patents

티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도 Download PDF

Info

Publication number
KR102244216B1
KR102244216B1 KR1020187037287A KR20187037287A KR102244216B1 KR 102244216 B1 KR102244216 B1 KR 102244216B1 KR 1020187037287 A KR1020187037287 A KR 1020187037287A KR 20187037287 A KR20187037287 A KR 20187037287A KR 102244216 B1 KR102244216 B1 KR 102244216B1
Authority
KR
South Korea
Prior art keywords
group
compound
acid
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR1020187037287A
Other languages
English (en)
Korean (ko)
Other versions
KR20190009377A (ko
Inventor
지안페이 왕
양 장
웬유안 주
슈후이 첸
Original Assignee
메드샤인 디스커버리 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메드샤인 디스커버리 아이엔씨. filed Critical 메드샤인 디스커버리 아이엔씨.
Publication of KR20190009377A publication Critical patent/KR20190009377A/ko
Application granted granted Critical
Publication of KR102244216B1 publication Critical patent/KR102244216B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020187037287A 2016-05-23 2017-05-23 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도 KR102244216B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610343321.0 2016-05-23
CN201610343321 2016-05-23
PCT/CN2017/085458 WO2017202291A1 (zh) 2016-05-23 2017-05-23 噻吩化合物及其合成方法和其在医药上的应用

Publications (2)

Publication Number Publication Date
KR20190009377A KR20190009377A (ko) 2019-01-28
KR102244216B1 true KR102244216B1 (ko) 2021-04-26

Family

ID=60411095

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037287A KR102244216B1 (ko) 2016-05-23 2017-05-23 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도

Country Status (12)

Country Link
US (1) US10829483B2 (zh)
EP (1) EP3466946B1 (zh)
JP (1) JP6724246B2 (zh)
KR (1) KR102244216B1 (zh)
CN (1) CN109790155B (zh)
AU (1) AU2017270858B2 (zh)
CA (1) CA3025078C (zh)
ES (1) ES2961901T3 (zh)
MX (1) MX2018014374A (zh)
NZ (1) NZ749427A (zh)
RU (1) RU2709473C9 (zh)
WO (1) WO2017202291A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3236903B1 (en) 2014-12-23 2021-04-21 Intellectual Property Associates, LLC Methods and formulations for transdermal administration
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
KR102246619B1 (ko) * 2017-11-23 2021-04-30 메드샤인 디스커버리 아이엔씨. Urat1 억제제의 결정형 및 그의 제조 방법
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
EP4053114B1 (en) * 2019-10-30 2024-10-09 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Thiophene derivatives as xanthine oxidase inhibitors and application thereof
BR112022010735A2 (pt) 2019-12-20 2022-08-23 Bayer Ag Tiofeno carboxamidas substituídos, ácidos tiofeno carboxílicos e derivados dos mesmos
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050589A1 (en) 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682391C (en) * 2007-04-11 2014-07-08 Kissei Pharmaceutical Co., Ltd. (aza)indole derivative and use thereof for medical purposes
DK2217577T3 (da) * 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
JP2012502050A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス,インク. 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
HUE037736T2 (hu) 2012-11-14 2018-09-28 Teijin Pharma Ltd Piridin származékok
WO2016150255A1 (zh) * 2015-03-24 2016-09-29 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN105399694B (zh) * 2015-12-11 2017-09-15 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050589A1 (en) 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases

Also Published As

Publication number Publication date
WO2017202291A1 (zh) 2017-11-30
US10829483B2 (en) 2020-11-10
AU2017270858A1 (en) 2019-01-17
JP2019519606A (ja) 2019-07-11
CN109790155B (zh) 2022-02-18
NZ749427A (en) 2019-11-29
MX2018014374A (es) 2019-05-20
US20200140423A1 (en) 2020-05-07
KR20190009377A (ko) 2019-01-28
AU2017270858B2 (en) 2019-09-19
JP6724246B2 (ja) 2020-07-15
EP3466946B1 (en) 2023-08-30
CA3025078A1 (en) 2017-11-30
BR112018074027A2 (pt) 2019-02-26
EP3466946A1 (en) 2019-04-10
ES2961901T3 (es) 2024-03-14
RU2709473C9 (ru) 2020-06-16
CN109790155A (zh) 2019-05-21
CA3025078C (en) 2021-04-13
EP3466946A4 (en) 2019-11-06
RU2709473C1 (ru) 2019-12-18

Similar Documents

Publication Publication Date Title
KR102244216B1 (ko) 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도
CA3050346C (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
US11339147B2 (en) Lactam compound as FXR receptor agonist
JP6717457B2 (ja) Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
KR102254660B1 (ko) A2a수용체 억제제로서의 축합 고리 유도체
KR20190056380A (ko) 항인플루엔자 바이러스 피리미딘 유도체
JP2019529386A5 (zh)
US10604513B2 (en) Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
KR101941794B1 (ko) 아미노설포닐계 화합물, 이의 제조 방법 및 용도
JP6951418B2 (ja) 抗hcmvウイルス化合物
US20180104220A1 (en) Imidazole compound
CN113582971B (zh) 一种小分子免疫抑制剂、其制备方法及其应用
US20120035361A1 (en) Selective inhibitors of excitatory amino acid transporter subtype 1 (eaat1/glast)
BR112018074027B1 (pt) Composto, ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso dos mesmos
EA040139B1 (ru) Производное азитидина

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant